Canada on Thursday authorized British drugmaker AstraZeneca Plc’s antibody-based therapy for preventing COVID-19 infections, giving itself another weapon against the disease as cases rise in the country.
Health Canada has cleared the drug - Evusheld - for use in individuals aged 12 years and older who are immune compromised and unlikely to mount an adequate immune response to COVID-19 vaccination or for whom COVID-19 vaccination is not recommended.
